Study shows in older people, type 2 diabetes is associated with a decline in brain function over 5 years

December 13, 2018

New research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) shows that in older people living in the community, type 2 diabetes (T2D) is associated with a decline in verbal memory and fluency over 5 years.

However, contrary to previous studies, the decrease in brain volume often found in older people with T2D was not found to be directly associated with cognitive decline during this time period. Yet compared with people without T2D, those with T2D had evidence of greater brain atrophy at the beginning of the study.

Previous research has shown that T2D can double the risk of dementia in older people. In this new study, Dr Michele Callisaya (University of Tasmania, Hobart, TAS, and Monash University, Melbourne, VIC, Australia) and colleagues aimed to discover whether type 2 diabetes is associated with greater brain atrophy and cognitive decline, and whether the two are linked. It is the first study to compare decline in both cognition and brain atrophy between people with and without T2D together in the same study.

The trial recruited 705 people aged 55-90 years from the Cognition and Diabetes in Older Tasmanians (CDOT) study. There were 348 people with T2D (mean age 68 years) and 357 without (mean age 72 years) who underwent brain MRI (lateral ventricular and total brain volume - measures of brain atrophy) and neuropsychological measures (global function and seven cognitive domains) at three time points over a mean follow-up period of 4.6 years.

The results were adjusted for age, sex, education and vascular risk factors including past or current smoking, heart attack, stroke, high blood pressure, high cholesterol, and body mass index. The authors reported there were significant associations found between T2D and greater decline in both verbal memory and verbal fluency.

Although people with diabetes had evidence of greater brain atrophy at the start of the study, there was no difference in the rate of brain atrophy between those with and without diabetes over the time course in this study. There was also no evidence in the study that the rate of brain atrophy directly impacted on the diabetes-cognition relationship.

In people without type 2 diabetes, verbal fluency slightly increased on average each year (0.004 SD/units per year), whereas it declined in those with type 2 diabetes (?0.023 SD/units per year). The authors say: "Such accelerated cognitive decline may contribute to executive difficulties in everyday activities and health behaviours --such as medication compliance -- which in turn may poorly influence future vascular health and cognitive decline, and possibly an earlier onset of dementia in those with type 2 diabetes."

They add: "Contrary to our hypotheses and results from previous cross-sectional studies, the rate of brain atrophy over these 5 years of study did not directly mediate associations between type 2 diabetes and cognitive decline. It is possible that greater accrual of cerebrovascular disease than occurred in our study may be more likely to reveal whether there is such a relationship."

They conclude: "In older community-dwelling people, type 2 diabetes is associated with a decline in verbal memory and fluency over approximately 5 years, but the effect of diabetes on brain atrophy may begin earlier, for example in midlife, given the evidence of greater brain atrophy in people with T2D at the start of the study. If this is the case, both pharmacological and lifestyle interventions to prevent brain atrophy in people with T2D may need to commence before older age."
-end-


Diabetologia

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.